Evidence map›Paper›PMID 38854751›Full record

ArticleChina CDC weekly2024

Comparison of 1 Versus 2 Doses of Quadrivalent Influenza Vaccine in 3-8-Year-Old Children with Different Immunological States - Jiangsu Province, China, 2021.

Qian Liu, Pengfei Jin, Jingxin Li, Xiaoqin Chen, Chenhao Wang, Qingbin Lu, Wei Jiang, Shixuan Zhang, Lairun Jin, Hongxin Pan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qian LiuSchool of Public Health, Southeast University, Nanjing City, Jiangsu Province, China.
Pengfei JinJiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing City, Jiangsu Province, China.
Jingxin LiSchool of Public Health, Southeast University, Nanjing City, Jiangsu Province, China.
Xiaoqin ChenDonghai County Center for Disease Control and Prevention, Donghai City, Jiangsu Province, China.
Chenhao WangChangchun Institute of Biological Products Co., Ltd. Changchun City, Jilin Province, China.
Qingbin LuDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, China.
Wei JiangChangchun Institute of Biological Products Co., Ltd. Changchun City, Jilin Province, China.
Shixuan ZhangChangchun Institute of Biological Products Co., Ltd. Changchun City, Jilin Province, China.
Lairun JinSchool of Public Health, Southeast University, Nanjing City, Jiangsu Province, China.
Hongxin PanJiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing City, Jiangsu Province, China.
Xue GuoChangchun Institute of Biological Products Co., Ltd. Changchun City, Jilin Province, China.
Fengcai ZhuSchool of Public Health, Southeast University, Nanjing City, Jiangsu Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

What is already known about this topic?: The quadrivalent influenza vaccine (QIV) provides protection against a broader range of influenza strains by including strains of influenza A/H1N1, A/H3N2, B/Yamagata, and B/Victoria. What is added by this report?: This study aimed to assess the immunogenicity and safety of administering a single dose compared to two doses of QIV in children, taking into consideration their previous influenza vaccination history. What are the implications for public health practice?: This study provides evidence supporting the use of a single dose of the QIV in children aged 3-8 years who have previously received two or more doses of influenza vaccine. However, children who have not been previously vaccinated with influenza vaccine should still adhere to the recommended schedule of receiving two doses.

Indexed as

ChildrenImmunogenicityInfluenza vaccinePublic healthSafetyVaccine

Identifiers

PMID38854751
PMCPMC11153867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.